Goldman Sach Cuts Price Target on Medicis (MRX)
Get Alerts MRX Hot Sheet
Price: $64.88 --0%
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 20 | New: 6
Rating Summary:
10 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 20 | New: 6
Join SI Premium – FREE
Goldman Sachs maintained a Buy rating on Medicis (NYSE: MRX) but lowered their price target to $42.00 (from $45.00) due to higher execution risk.
"We expect some pressure on the shares given increased execution risk, but maintain our Buy rating with the view that the overall growth story is still intact and the shares already reflected some of these concerns. We also see support from significant cash flow generation, a strong balance sheet, and meaningful M&A potential," said analyst Gregory Waterman.
For an analyst ratings summary and ratings history on Medicis click here. For more ratings news on Medicis click here.
Shares of Medicis closed at $33.31 yesterday.
"We expect some pressure on the shares given increased execution risk, but maintain our Buy rating with the view that the overall growth story is still intact and the shares already reflected some of these concerns. We also see support from significant cash flow generation, a strong balance sheet, and meaningful M&A potential," said analyst Gregory Waterman.
For an analyst ratings summary and ratings history on Medicis click here. For more ratings news on Medicis click here.
Shares of Medicis closed at $33.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northern Oil and Gas (NOG) PT Lowered to $29 at Mizuho
- Bernstein SocGen Group Starts Asymchem Laboratories Tianjin Co Ltd (002821:CH) at Outperform
- Evercore ISI Starts SpaceX (SPCX) at Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share